# Lapatinib in Combination With Docetaxel in Patients With HER-2 Positive Advanced or Metastatic Breast Cancer

> **NCT01044485** · PHASE1,PHASE2 · COMPLETED · sponsor: **Centre Georges Francois Leclerc** · enrollment: 17 (actual)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **DRUG:** lapatinib
- **DRUG:** docetaxel

## Key facts

- **NCT ID:** NCT01044485
- **Lead sponsor:** Centre Georges Francois Leclerc
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-11
- **Primary completion:** 2011-11
- **Final completion:** —
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2012-09-25

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01044485

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01044485, "Lapatinib in Combination With Docetaxel in Patients With HER-2 Positive Advanced or Metastatic Breast Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01044485. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*